Germline testing to assess risk for specific types of prostate cancer

The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …

Prediction of risk for aggressive prostate cancer among Black males

A newly published paper has now suggested that data from a single PSA test carried out when the men are between 40 and 64 years of age can be used to project risk for aggressive prostate cancer among African-American men. … READ MORE …

A poorly informed public and risk for cancer

A recent report from the Prostate Cancer Foundation (PCF), here in the US, found — unsurprisingly to your sitemaster, at least — that the average American remains very poorly informed about risk for prostate cancer and associated issues. … READ MORE …

But annual, mass, population-based PSA screening really works (or does it?)

A new and potentially controversial article in Urology (the “Gold Journal”) has just suggested that regular, mass, population-based screening of men for risk of prostate cancer every 12 to 18 months remains a good idea. … READ MORE …

It’s Prostate Cancer Awareness Month, again …

… and during Prostate Cancer Awareness Month men and their families are regularly subjected to messaging about the importance of getting “screened” for risk of prostate cancer. … READ MORE …

Your genetics can accurately predict your age-related prostate cancer risk

Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …

Experts create guidelines for screening prostate cancer patients for inherited cancer risk genes

Knowing whether you carry inherited cancer risk genes can help you to make the best decisions for your treatment and for your family. … READ MORE …

Reports from the EAU “Update on Prostate Cancer” meeting in Vienna

The European Association of Urology (EAU) “Update on Prostate Cancer” meeting was held in Vienna, Austria, on Friday and Saturday, and Dr. Zachary Klaassen was again busy providing summary reports on presentations for UroToday. … READ MORE …

The prostate cancer “screening” controversy … an update

Yesterday we mentioned a new paper on PSA screening by Tsodikov et al. in the Annals of Internal Medicine. We have now had the chance to read the full text of that paper, as well as the associated editorial by Vickers in the same issue of the journal. … READ MORE …

And now PSA “screening” does save lives again … maybe

A new article just published in the Annals of Internal Medicine has suggested that PSA testing really does save lives. But the new article isn’t based on any really new data. … READ MORE …

An update on “screening” for prostate cancer: four perspectives

To quote the abstract of the paper discussed below, the use of the PSA test to screen for risk of prostate cancer “in men at normal risk of prostate cancer is one of the most contested issues in cancer screening.” No! Really? … READ MORE …

It’s not “as big a deal as you might think”

What isn’t as big a deal as we might think? According to The New York Times this morning, the US Preventive Services Task Force’s new recommendations about prostate cancer screening. … READ MORE …

Can the Decipher test accurately project risk for metastasis post-surgery?

A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …

Genetics, genomics, targeted therapy, and the costs of care

A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …

Prostate cancer detection and associated risk management

Dr. Michael Barry has been a long-time advocate for caution in the appropriate use of PSA testing and for awareness of the risks of over-treatment of low-risk forms of prostate cancer. … READ MORE …